SALT LAKE CITY, Feb. 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced the publication of two peer-reviewed journal articles describing the clinical data to date for Azixa™ (MPC-6827, verubulin). Azixa is the Company’s lead compound currently under evaluation in a two-arm, Phase 2b clinical study for first-line treatment of glioblastoma multiforme (GBM), an aggressive form of primary brain cancer.
